In this study, we demonstrate that inhibition of EHMT1 and EHMT2 with specific chemical inhibitors in several CML cell lines sensitizes cells to interferon and imatinib treatments. The gene discussed is EHMT2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.